
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Consolidation Therapy for Locally Advanced NSCLC
Case: A 59-year-old Woman With Locally Advanced NSCLC


